Browsing by Author "Marjanovic-Haljilji, Marija (57325486100)"
Now showing 1 - 3 of 3
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication Anatomical Brain Changes and Cognitive Abilities in Patients with Obstructive Sleep Apnea Syndrome and Nonalcoholic Fatty Liver Disease(2021) ;Filipovic, Branka (22934489100) ;Đuric, Vesna (57192540095) ;Filipovic, Natasa (57325486000) ;Kiurski, Stanimir (57220806455) ;Al Kiswani, Jamal (57326058400) ;Markovic, Branka (55887269300) ;Laketic, Darko (25936376800) ;Marjanovic-Haljilji, Marija (57325486100) ;Kapor, Slobodan (24321238000)Filipovic, Branislav R. (56207614900)Obstructive sleep apnea (OSA) is characterized by repetitive complete or partial collapse of the upper airway and reduction of airflow during sleep. It is associated with significantly increased daytime muscle sympathetic nerve activity thought to result from the repetitive intermittent periods of hypoxemia during sleep and brain alterations that are likely to result. Different brain regions are affected by subsequent hypoxia/anoxia. Neurodegenerative processes result in measurable atrophy of cortical gray matter in the temporal lobes and posterior cingulate cortex, as well as in subcortical structures such as the hippocampus, amygdala, and thalamus. This study involved a group of firstly diagnosed, therapy-naive, nonalcoholic fatty liver disease (NAFLD) patients, out of which 144 (96 males and 48 females), aged 34-57 (mean 47.88 ± 6.07), satisfied the recruiting criteria for the study and control groups. All the patients underwent MRI scanning, polysomnography testing, and cognitive evaluation. Cognitively, worse results were obtained in the group with OSA (p<0.05) and NAFLD (p=0.047). A significant decrease in volumes of cortical and subcortical structures was revealed (p<0.001). In conclusion, brain deterioration followed by cognitive impairment is, most likely, the result of intermittent hypoxia and anoxia episodes that initiate the domino process of deteriorating biochemical reactions in the brain. © 2021 Branka Filipovic et al. - Some of the metrics are blocked by yourconsent settings
Publication Molecular Aspects of MAFLD—New Insights on Pathogenesis and Treatment(2023) ;Filipovic, Branka (22934489100) ;Marjanovic-Haljilji, Marija (57325486100) ;Mijac, Dragana (16550439600) ;Lukic, Snezana (25028136800) ;Kapor, Suncica (58198272500) ;Kapor, Slobodan (24321238000) ;Starcevic, Ana (49061458600) ;Popovic, Dusan (37028828200)Djokovic, Aleksandra (42661226500)Metabolic-associated liver disease (MAFLD) affects up to 70% of overweight and more than 90% of morbidly obese people, and its pathogenesis is rather complex and multifactorial. The criteria for MAFLD include the presence of hepatic steatosis in addition to one of the following three criteria: overweight or obesity, presence of type 2 diabetes mellitus (T2DM), or evidence of metabolic dysregulation. If the specific criteria are present, the diagnosis of MAFLD can be made regardless of alcohol consumption and previous liver disease. The pathophysiological mechanisms of MAFLD, including inflammation, lipotoxicity, mitochondrial disfunction, and oxidative stress, as well as the impact of intestinal gut microbiota, are constantly being elucidated. Treatment strategies that are continually emerging are based on different key points in MAFLD pathogenesis. Yet, the ideal therapeutic option has still not been found and future research is of great importance, as MAFLD represents a multisystemic disease with numerous complications. © 2023 by the authors. - Some of the metrics are blocked by yourconsent settings
Publication Molecular Aspects of MAFLD—New Insights on Pathogenesis and Treatment(2023) ;Filipovic, Branka (22934489100) ;Marjanovic-Haljilji, Marija (57325486100) ;Mijac, Dragana (16550439600) ;Lukic, Snezana (25028136800) ;Kapor, Suncica (58198272500) ;Kapor, Slobodan (24321238000) ;Starcevic, Ana (49061458600) ;Popovic, Dusan (37028828200)Djokovic, Aleksandra (42661226500)Metabolic-associated liver disease (MAFLD) affects up to 70% of overweight and more than 90% of morbidly obese people, and its pathogenesis is rather complex and multifactorial. The criteria for MAFLD include the presence of hepatic steatosis in addition to one of the following three criteria: overweight or obesity, presence of type 2 diabetes mellitus (T2DM), or evidence of metabolic dysregulation. If the specific criteria are present, the diagnosis of MAFLD can be made regardless of alcohol consumption and previous liver disease. The pathophysiological mechanisms of MAFLD, including inflammation, lipotoxicity, mitochondrial disfunction, and oxidative stress, as well as the impact of intestinal gut microbiota, are constantly being elucidated. Treatment strategies that are continually emerging are based on different key points in MAFLD pathogenesis. Yet, the ideal therapeutic option has still not been found and future research is of great importance, as MAFLD represents a multisystemic disease with numerous complications. © 2023 by the authors.
